• Over the past two weeks, board directors and senior management team members have acquired a total of 4,521,000 common shares of ScreenPro
  • A total of 1,680,000 shares were purchased by senior management team members on the open market between April 5, 2022, and April 6, 2022
  • ScreenPro is a screening and medical technology company that provides turnkey screening solutions with its proprietary medical alerting software
  • ScreenPro Security Inc. (SCRN) opened trading at $0.07

Over the past two weeks, several ScreenPro (SCRN) company insiders have acquired a total of 4,521,000 common shares.

A total of 1,680,000 shares were purchased by senior management team members on the open market between April 5, 2022, and April 6, 2022.

Details of the purchase are as follows:

  • Michael Yeung, the Chairman, purchased 435,000 shares
  • Lena Kozovski, the CEO, purchased 395,000 shares
  • Paul Haber, CFO, purchased 400,000 shares
  • Youngcho Lee, a director, purchased 450,000 shares

“Senior management has great confidence in the company and strongly believes in the value of our shareholders,” said CEO Lena Kozovski.

“I want to thank the members of the company for their continued support and belief in us as we continue to grow,” she added.

ScreenPro is a screening and medical technology company that provides turnkey screening solutions with its proprietary medical alerting software.

ScreenPro Security Inc. (SCRN) opened trading at $0.07.

More From The Market Online

PharmAla Biotech launches educational portal for MDMA

PharmAla Biotech (CSE:MDMA) launches its Prescribers Portal for medical practitioners to learn more about MDMA.

BlackBerry expands AI-powered cybersecurity service

BlackBerry (TSX:BB) releases the new and expanded CylanceMDR, a managed detection and response tool backed by its Cylance AI platform.

Qualcomm stock jumps on Q2 2024 earnings

Qualcomm (NDAQ:QCOM) shares rise nearly 10 per cent early Thursday on better-than-expected adjusted earnings and strong revenue guidance.

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.